NOVEL APPROACH OF PHARMACEUTICAL CO-CRYSTALS FOR POORLY SOLUBLE DRUGS

Curcumin a polyphenolic active pharmaceutical ingredient, extracted from curcuma longa possess a wide variety of pharmacological activities. The utility of curcumin is limited by its, lack of water solubility, and relatively low invivo bioavailability. In this context, Co-crystal approach are non-ionic supramolecular complexes and can be used to address physical property issues such as solubility, stability and bioavailability in pharmaceutical development without changing the chemical composition of the API. Novel co-crystal of curcumin with methyl paraben was obtained by liquid assisted grinding method by (1:1) molar ratio. This formulation was evaluated for Anti-inflammatory activity. FT-IR, DSC, PXRD results delineation of the hierarchy of hydrogen bonding between complementary functional groups or supramolecular heterosynthons can be accomplished. The percentage of inhibition in paw edema after 3 h were recorded 67.71 % in case of Indomethacin, 55.73% in case of 100 mg/kg of Curcumin, 66.67 % in case of 100 mg/kg of Curcumin co-crystals respectively.